相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Impact of EGFR-TKI Treatment on the Tumor Immune Microenvironment in EGFR Mutation-Positive Non-Small Cell Lung Cancer
Kohsuke Isomoto et al.
CLINICAL CANCER RESEARCH (2020)
Concomitant genetic alterations having greater impact on the clinical benefit of EGFR-TKIs in EGFR-mutant advanced NSCLC than BIM deletion polymorphism
Si-Yang Liu et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2020)
Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC
D. Ross Camidge et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
Anna Maria Rachiglio et al.
CANCERS (2019)
Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas
Lawrence A. Donehower et al.
CELL REPORTS (2019)
Risk stratification for lung adenocarcinoma on EGFR and TP53 mutation status, chemotherapy, and PD-L1 immunotherapy
Chih-Hsun Wu et al.
CANCER MEDICINE (2019)
Co-mutations of TP53 and KRAS serve as potential biomarkers for immune checkpoint blockade in squamous-cell non-small cell lung cancer: a case report
Cheng Fang et al.
BMC MEDICAL GENOMICS (2019)
The Network of Cancer Genes (NCG): a comprehensive catalogue of known and candidate cancer genes from cancer sequencing screens
Dimitra Repana et al.
GENOME BIOLOGY (2019)
Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy
Ferdinandos Skoulidis et al.
NATURE REVIEWS CANCER (2019)
The prognostic value of TP53 and its correlation with EGFR mutation in advanced non-small cell lung cancer, an analysis based on cBioPortal data base
Xiao-Dong Jiao et al.
LUNG CANCER (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial
Zhijie Wang et al.
LANCET RESPIRATORY MEDICINE (2018)
Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer
Shaodong Hong et al.
JAMA ONCOLOGY (2018)
The biology and management of non-small cell lung cancer
Roy S. Herbst et al.
NATURE (2018)
The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations-The Lung Cancer Mutation Consortium (LCMC2)
Dara L. Aisner et al.
CLINICAL CANCER RESEARCH (2018)
Impact of TP53 Mutations on Outcome in EGFR-Mutated Patients Treated with First-Line Tyrosine Kinase Inhibitors
Matteo Canale et al.
CLINICAL CANCER RESEARCH (2017)
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
Zhong-Yi Dong et al.
CLINICAL CANCER RESEARCH (2017)
Lung cancer: current therapies and new targeted treatments
Fred R. Hirsch et al.
LANCET (2017)
Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes
Paul A. VanderLaan et al.
LUNG CANCER (2017)
Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC)
Catherine Labbe et al.
LUNG CANCER (2017)
Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer
T. S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations
Ying Cheng et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
EGFR Mutation Status and First-Line Treatment in Patients with Stage III/IV Non-Small Cell Lung Cancer in Germany: An Observational Study
Wolfgang Schuette et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2015)
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma
Emilio Bria et al.
ONCOTARGET (2015)
Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non-Small Cell Lung Cancer
Miguel A. Molina-Vila et al.
CLINICAL CANCER RESEARCH (2014)
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2014)
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study
Takashi Seto et al.
LANCET ONCOLOGY (2014)
Should epidermal growth factor receptor tyrosine kinase inhibitors be considered ideal drugs for the treatment of selected advanced non-small cell lung cancer patients?
Antonio Rossi et al.
CANCER TREATMENT REVIEWS (2013)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Single-Molecule Detection of Epidermal Growth Factor Receptor Mutations in Plasma by Microfluidics Digital PCR in Non-Small Cell Lung Cancer Patients
Tony K. F. Yung et al.
CLINICAL CANCER RESEARCH (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Using Whole Genome Amplification (WGA) of Low-Volume Biopsies to Assess the Prognostic Role of EGFR, KRAS, p53, and CMET Mutations in Advanced-Stage Non-small Cell Lung Cancer (NSCLC)
Elaine H. Lim et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
The role of the EGFR signaling in tumor microenvironment
Antonella De Luca et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2008)
TP53 mutations and survival in squamous-cell carcinoma of the head and neck
M. Luana Poeta et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
分享论文
